Syre Therapeutics (SYPR) PT Raised to $106 at Leerink Partners, 'initial SKYLINE results represent best-case data for SPY001'
Tweet Send to a Friend
(Updated - April 13, 2026 2:39 PM EDT)
Leerink Partners analyst Thomas Smith raised the price target on Syre ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst Thomas Smith raised the price target on Syre ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
